CLAIMS:

1. Use of a neutralising antibody which binds human IL-17A and human IL-17F having a light chain and a heavy chain wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:7 and the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3, in the manufacture of a medicament for use in the treatment or prophylaxis of a pathological condition selected from the group consisting arthritis, rheumatoid arthritis, psoriatic arthritis, systemic onset juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE), asthma, chronic obstructive airways disease (COAD), chronic obstructive pulmonary disease (COPD), Crohn's disease, Ulcerative colitis, ankylosing spondylitis and other spondyloarthropathies, psoriasis, atopic dermatitis, lung fibrosis scleroderma, and systemic sclerosis.

2. The use of claim 1 wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:9.

3. The use according to claim 1 or claim 2 wherein the antibody which also binds the IL-17A/IL-17F heterodimer.

4. The use according to any one of claims 1 to 3, wherein the antibody is a whole antibody or functionally active fragment thereof.

5. The use according to claim 4 where the antibody fragment is selected from the group consisting of a Fab, Fab', F(ab')2, scFv and Fv fragment.

6. The use according to any one of claims 1 to 3 wherein the antibody is a multi-specific antibody.

7. Use of a neutralising antibody which binds human IL-17A and human IL-17F, having a heavy chain comprising the sequence given in SEQ ID NO:15 and a light chain comprising the sequence given in SEQ ID NO: 11, in the manufacture of a medicament for use in the treatment or prophylaxis of a pathological condition selected from the group consisting of arthritis, rheumatoid arthritis, psoriatic arthritis, systemic onset juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE), asthma, chronic obstructive airways disease (COAD), chronic obstructive pulmonary disease (COPD), Crohn's disease, Ulcerative colitis, ankylosing spondylitis and other spondyloarthropathies, psoriasis, atopic dermatitis, lung fibrosis, scleroderma, and systemic sclerosis.